0001209191-22-060077.txt : 20221206 0001209191-22-060077.hdr.sgml : 20221206 20221206173147 ACCESSION NUMBER: 0001209191-22-060077 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20221202 FILED AS OF DATE: 20221206 DATE AS OF CHANGE: 20221206 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Ross Thomas M. CENTRAL INDEX KEY: 0001874572 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-40674 FILM NUMBER: 221448579 MAIL ADDRESS: STREET 1: C/O MAXCYTE, INC. STREET 2: 22 FIRSTFIELD ROAD, SUITE 110 CITY: GAITHERSBURG STATE: MD ZIP: 20878 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: MAXCYTE, INC. CENTRAL INDEX KEY: 0001287098 STANDARD INDUSTRIAL CLASSIFICATION: SERVICES-COMMERCIAL PHYSICAL & BIOLOGICAL RESEARCH [8731] IRS NUMBER: 522210438 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 22 FIRSTFIELD ROAD STREET 2: SUITE 250 CITY: GAITHERSBURG STATE: MD ZIP: 20878 BUSINESS PHONE: 301-517-5556 MAIL ADDRESS: STREET 1: 22 FIRSTFIELD ROAD STREET 2: SUITE 250 CITY: GAITHERSBURG STATE: MD ZIP: 20878 FORMER COMPANY: FORMER CONFORMED NAME: MAXCYTE INC DATE OF NAME CHANGE: 20040415 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2022-12-02 0 0001287098 MAXCYTE, INC. MXCT 0001874572 Ross Thomas M. C/O MAXCYTE, INC. 9713 KEY WEST AVENUE, SUITE 400 ROCKVILLE MD 20850 0 1 0 0 EVP, Global Sales & Marketing Common Stock 2022-12-02 4 M 0 15000 1.08 A 15000 D Common Stock 2022-12-02 4 S 0 15000 6.02 D 0 D Common Stock 2022-12-05 4 M 0 14133 1.08 A 14133 D Common Stock 2022-12-05 4 S 0 14133 5.59 D 0 D Employee Stock Option (right to buy) 1.08 2022-12-02 4 M 0 15000 0.00 D 2026-06-13 Common Stock 15000 45734 D Employee Stock Option (right to buy) 1.08 2022-12-05 4 M 0 14133 0.00 D 2026-06-13 Common Stock 14133 31601 D The sales and option exercises reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 6, 2022. This exercise price is in U.S. Dollars and reflects the conversion of British pounds, the currency in which the exercise price was expressed at the time of grant. The price reported is a weighted average price. The shares were sold in multiple transactions at prices ranging from $6.00 to $6.05, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4. The price reported is a weighted average price. The shares were sold in multiple transactions at prices ranging from $5.35 to $5.98, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4. This option is fully vested and exercisable. /s/ Brian F. Leaf, attorney-in-fact 2022-12-06